February 25, 2025: Francis Medical completes enrollment in the company's VAPOR 2 Pivotal Study for Vanquish Prostate Cancer Treatment
January 8, 2025: Francis Medical raises record $80M in Series C to fund its VAPOR 2 study and U.S. launch of Vanquish, its proprietary prostate cancer treatment
In a revealing interview with Citeline Commercial's Medtech Insight, CEO Mike Kujak discusses how Francis Medical's Vanquish system is set to redefine prostate cancer treatment
Francis Medical CEO Mike Kujak shares the highs and lows of being the CEO of a medtech startup and provides a window into the journey at Francis Medical
Vanquish Water Vapor Ablation System featured in the October 2023 Minnesota Physician Journal
August 1, 2023: Francis Medical today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its Vanquish minimally invasive water vapor ablation therapy
July 19, 2023: Francis Medical today announced the first patient has been treated in the company’s VAPOR 2 pivotal clinical study evaluating the safety and efficacy of its Vanquish minimally invasive water vapor ablation therapy for managing prostate cancer
January 26, 2023: Francis Medical has appointed to its board of directors Andrew Cleeland, a leader with extensive experience in healthcare innovation and the development and deployment of new medical technologies
Francis Medical Founder and Chief Technology Officer, Michael Hoey, joins The Focal Therapy Clinic OnFocus podcast to discuss a new approach to focal therapy, water vapor therapy, and its adoption into medical practice
September 15, 2021: Francis Medical today announced the completion of the company’s $55.0 million Series B equity financing. The company plans to use the Series B proceeds to fund the development of its proprietary prostate cancer treatment through FDA 510(k) approval, which includes a pivotal clinical study (VAPOR 2) for the management of prostate cancer, scheduled to begin enrollment in August 2022
June 8, 2021: Francis Medical announces positive data from its Vapor 1 IDE Study for water vapor ablation of prostate cancer. These promising results support the intent of this therapy to manage clinically significant disease while decreasing morbidities associated with currently used prostate cancer treatments
In an interview for Medical Alley's "For the Record," the founder and CTO of Francis Medical, Michael Hoey, shares why he sought a more compassionate approach for treating prostate cancer and how he discovered water vapor technology. He also gives a window into how things are progressing at Francis Medical
October 5, 2020: CCX Media visited Francis Medical to interview President and CEO Mike Kujak, and get an inside look at how Francis Medical is thriving and moving forward during the COVID-19 pandemic. This two-minute video includes recent news about a $4M investment by Coloplast
September 29, 2020: Francis Medical Adds Urology Company Coloplast to Its Roster of Investors. The $4 million equity investment will support the company in optimizing its product design and executing a pivotal U.S. study
This video demonstrates how water vapor therapy will provide a revolutionary new prostate cancer treatment that is tough on prostate cancer yet gentle on patients
The Vanquish® Water Vapor Ablation System is indicated for the thermal ablation of targeted prostate tissue via a transurethral approach. The FDA has not evaluated the Vanquish System for the treatment of any disease, including prostate cancer, or evaluated the Vanquish System for any long-term prostate cancer treatment outcomes.
Federal law (USA) restricts this device to sale by or on the order of a physician.
Refer to the device User Manual for a list of contraindications, warnings, and cautions.
Training: Do not operate the Vanquish System without completing Francis Medical-provided physician training. Untrained operation of the device may lead to improper use. Improper use can result in patient injury or equipment malfunction.